Is ImmunityBio, Inc. (IBRX) a Buy, Sell, or Hold?
ImmunityBio, Inc.
NASDAQ:IBRX
$7.88 USD
$0.09 (1.16%)
- Volume
- 7.47M
- Average Volume
- 13.62M
- Market Capitalization
- $8.25B
- P/E Ratio
- -9.23
- Dividend Yield
- 0.00%
- Price Target
- $12.00
- Year High
- $12.43
- Year Low
- $1.95
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.67
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Richard Gerald Adcock |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | IBRX |
| CUSIP | 45256X103 |
| CIK | 0001326110 |
| Web | https://immunitybio.com |
| Phone | 858 633 0300 |
| Currency | USD |
| Employees | 691 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -1.29 |
| Payout Ratio | 0.00 |
| Current Ratio | 6.67 |
| Quick Ratio | 6.66 |
| Cash Ratio | 3.02 |
Sales & Book Value
| Annual Sales | $113.29M |
| Price / Sales | 58.54 |
| Cash Flow | -0.29 |
| Price / Cash Flow | -27.57 |
| Price / Book | -9.30 |
Price Target and Rating
| Average Stock Price Forecast | $12.00 |
| High Stock Price Forecast | $15.00 |
| Low Stock Price Forecast | $12.00 |
| Forecast Upside/Downside | -34.33% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 5 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.38 |
| Trailing P/E Ratio | -9.23 |
| PEG Ratio | 0.07 |
| P/E Growth | 0.07 |
| Net Income | $-351.4M |
| Net Margin | -606.15% |
| Pretax Margin | -606.13% |
| Return on Equity | 138.69% |
| Return on Assets | -132.15% |
Financials Score
| AltmanZ Score | -8.98 |
| Piotroski Score | 3.00 |
| Working Capital | 385M |
| Total Assets | 646.64M |
| Ebit | -742.37M |
| Market Cap | 8.38B |
| Total Liabilities | 1.52B |
Poll Results
About ImmunityBio, Inc. (NASDAQ:IBRX) Stock
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various ... liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Squeeze Watch: 10 Stocks Bears Love to Hate Most Right Now
2026-07-13 14:29:04
Short‑interest screens are lighting up with a tight cluster of mid‑ and large‑cap names where bearish bets have gone all‑in, turning these stocks into live‑wire squeeze candidates rather than sleepy laggards.
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout
2026-07-10 12:04:38
Biotech is the story at midday Friday, and it's not a pretty one for shareholders who chased the sector's monster 2026 run.
ImmunityBio: A Long-Term Bull Case Worth Watching
2026-07-07 04:07:39
ImmunityBio is pivoting from a single-product Anktiva focus to a broad immunotherapy platform, emphasizing memory-like cytokine-enriched NK cells (M-ceNK). Key near-term catalysts include the pivotal QUILT-2.005 bladder cancer trial, lymphopenia indication expansion, and the glioblastoma (GBM) program, each validating the immune-restoration thesis. IBRX trades at a significant premium (65x trailing sales, 44x forward sales), reflecting high expectations for Anktiva's transition to first-line therapies and broader platform validation.
ImmunityBio (IBRX) Moves 11.8% Higher: Will This Strength Last?
2026-06-29 09:01:15
ImmunityBio (IBRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026
2026-06-01 14:00:00
ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a commercial-stage immunotherapy company, today announced two poster presentations and one online publication at
ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026
2026-06-01 13:51:00
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced two poster presentations and one online publication at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 2, 2026, in Chicago. The presentations span two randomized Phase 3 trials in advanced NSCLC and a matched adjusted indirect comparison (MAIC) in BCG unresponsive non-muscle invasive bladder cancer (NMIBC), and collectively e.
IBRX and the BCG Shortage: Deals That Could Expand Demand
2026-05-29 14:31:07
ImmunityBio targets the BCG shortage with new supply deals and label expansion efforts that could strengthen Anktiva demand in bladder cancer.
ImmunityBio: Anktiva Explained and What Comes Next
2026-05-29 14:25:40
IBRX's Anktiva drives a 668% revenues jump in 2025 as ImmunityBio expands bladder cancer approvals and pursues new catalysts.
Frequently Asked Questions
-
What is the current ImmunityBio, Inc. (IBRX) stock price?
-
ImmunityBio, Inc.(NASDAQ:IBRX) stock price is $7.88 in the last trading session. During the trading session, IBRX stock reached the peak price of $12.43 while $1.95 was the lowest point it dropped to. The percentage change in IBRX stock occurred in the recent session was 1.16% while the dollar amount for the price change in IBRX stock was $0.09.
-
IBRX's industry and sector of operation?
-
The NASDAQ listed IBRX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of IBRX?
-
Patrick Soon-Shiong FRCS | Founder, Executive Chairman and Global Chief Scientific & Medical Officer
Sandeep K. Reddy | Chief Medical Officer
Regan J. Lauer | Chief Accounting Officer
Leonard S. Sender | Chief Medical Officer of Liquid Tumors & Cell Therapy
Enrique Diloné | Chief Technology Officer -
How many employees does IBRX have?
-
Number of IBRX employees currently stands at 691. IBRX operates from 3530 John Hopkins Court, San Diego, CA 92121, US.
-
Link for IBRX official website?
-
Official Website of IBRX is: https://immunitybio.com
-
How do I contact IBRX?
-
IBRX could be contacted at phone #858 633 0300 and can also be accessed through its website. IBRX operates from 3530 John Hopkins Court, San Diego, CA 92121, US.
-
How many shares of IBRX are traded daily?
-
The average number of IBRX shares traded daily for last 3 months was 13.62M.
-
What is the market cap of IBRX currently?
-
The market value of IBRX currently stands at $8.25B with its latest stock price at $7.88